Compare MOLN & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOLN | OSUR |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.8M | 177.2M |
| IPO Year | 2021 | 1986 |
| Metric | MOLN | OSUR |
|---|---|---|
| Price | $4.52 | $2.59 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $4.00 | $3.00 |
| AVG Volume (30 Days) | 6.4K | ★ 822.6K |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $125,703,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,000.00 | $3.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.36 | $2.08 |
| 52 Week High | $5.99 | $4.22 |
| Indicator | MOLN | OSUR |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 53.13 |
| Support Level | $3.99 | $2.33 |
| Resistance Level | $4.61 | $2.61 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 84.92 | 91.43 |
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.